Affinium Launches the Development of a New Class of Antibiotics for Superbugs
Affinium’s MRSA antibiotic represents a potential breakthrough as the first antibiotic to a newly targeted bacterial pathway in 40 years
Toronto, Ontario, February 16, 2005 — Affinium Pharmaceuticals announced today that it has selected a drug candidate for development of a novel MRSA antibiotic to be used in hospital and community settings. The candidate is one of multiple compounds from Affinium’s Galapagos program.
“It is important that our development candidate operates via a novel mechanism of action with very novel chemistry, and distinct from any other antibiotic on the market. Our drug candidates selectively inhibit a bacterial pathway to kill bacteria without any detectable side effects to the analogous human pathway. Because of their unique way of working, we believe resistance will be slow to develop.” said Judd Berman, Ph.D., Senior Vice President of Chemistry. “Our team selected Affinium’s first development candidate after evaluating animal data from over 150 front runner compounds with potent MRSA activity from this new antibiotic class. We selected the first compound for its potential as an IV and oral antibiotic for hospital and community MRSA.”
“The recent advancements of our MRSA program represent an important milestone in the development of a new class of breakthrough antibiotics for us. The last time the industry targeted a new pathway with an antibiotic that bugs had never seen before was the fluoroquinolone class in the 1960s. Fluoroquinolones now represent over $7 billion in world wide annual sales,” said Dr. John D. Mendlein, Affinium’s Chairman and CEO.
“In its early stages, our Galapagos project was probably too pioneering for big pharma to support. There were too many “news” – new target, new pathway, new chemistry, new paradigm and new drug design technology. However, Affinium’s novel approach to drug discovery has allowed our team to accelerate the development of our MRSA program. In addition, we are currently working to leverage our new class for commercially attractive second generation products to treat other serious bacterial infections. With further scientific insights, substantial additional investment in R&D and more hard work, we have the potential to turn our Galapagos project into multiple medical breakthrough products for patients who are suffering or dying from a wide range of bacterial infections. Given almost daily reports of antibiotic resistant infections both in institutional and community settings worldwide, we believe our Galapagos franchise is potentially of great significance to public health and the overall reduction of health care costs.”
About Affinium Pharmaceuticals
Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines. AFN-1252 utilizes a unique mechanism of action by directly inhibiting the function of the bacterial fatty acid synthesis (FAS) II pathway. Affinium's FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors of a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway.
Duo an num quam fuisset sadipscing, elit animal doc endi enum num ut.